Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The record describes a completed Phase 2 study of guadecitabine and pembrolizumab for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It also includes participant eligibility, treatment plans, outcome measures, study documents, and investigator information.
    Difference
    57%
    Check dated 2026-11-08T00:39:15.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T18:30:23.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T19:33:25.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T19:47:32.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1; the page otherwise continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T20:20:06.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error screen, replacing the study content; accompanying additions include basic navigation text (Home, Revision: v3.7.0) while a large portion of study-related content appears to have been removed.
    Difference
    20%
    Check dated 2026-09-19T19:16:22.000Z thumbnail image

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.